No­var­tis strikes car­dio­vas­cu­lar dis­cov­ery deal with Flag­ship’s Pro­Found

No­var­tis has signed up pro­teomics spe­cial­ist Pro­Found Ther­a­peu­tics to pin­point “pre­vi­ous­ly un­known” pro­teins to be in­ves­ti­gat­ed as car­dio­vas­cu­lar drugs and drug tar­gets in a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER